Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients

Blood Purification

Volumn 25, Issue 1, 2006, Pages 31-35

  Ofsthun, Norma J ^a   Lazarus, J Michael ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Anemia; Dialysis; Erythropoietin; Hemoglobin; Medicare

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; COMPUTER SYSTEM; CONFERENCE PAPER; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEALTH POLICY; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 33845772218     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096394     Document Type: Conference Paper

References (4)

1. Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992;51:76-89.
2. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-1914.
3. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998;32(6 suppl 4):S133-S141.
4. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-124.